Exscientia Plc - EXAI STOCK NEWS

Exscientia plc (Nasdaq: EXAI) will announce financial results for Q4 and full year 2023 on March 21, 2024. A conference call and webcast will be held to discuss business updates and financial performance.

Exscientia plc (Nasdaq: EXAI) management to participate in investor conferences in March, including TD Cowen 44th Annual Health Care Conference, Barclays 26th Annual Global Healthcare Conference, and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Webcasts of the presentations will be available on the company's website.

Exscientia plc (Nasdaq: EXAI) has announced the initiation of the EXCYTE-2 study, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response. The study aims to collect blood and bone marrow samples from first-line patients with AML, with an option to expand to second-line patients, representing areas of high unmet medical need with low survival rates. The study will also evaluate the activity of EXS74539 (‘539), Exscientia’s LSD1 inhibitor, in a large clinically annotated sample set, with the potential to support the ongoing development of ‘539, particularly in the selection of patients for future clinical trials. This study builds on other previously initiated precision medicine focused studies, including EXALT-1 and EXCYTE-1, and continues the company's focus on establishing AI-led ex vivo drug testing in human tissue samples as the most comprehensive strategy for preclinical testing of novel therapies, additive to mouse and other animal models.

Exscientia plc (Nasdaq: EXAI) founder and Chief Executive, Professor Andrew Hopkins, has been appointed Commander of the Order of the British Empire (CBE) for services to Science and Innovation by His Majesty King Charles III. This recognition follows multiple prestigious honours recently received by both Andrew and Exscientia, the AI-driven precision medicine company he leads. Exscientia has won the Prix Galien USA for Best Digital Health Solution in late 2022 and the Prix Galien UK in the same category in May 2023. Andrew was also elected for life to two of the UK’s national academies, the Royal Society and the Academy of Medical Sciences. Additionally, Exscientia was named to the inaugural Fortune 50 AI Innovators list in November 2023.

Exscientia plc (Nasdaq: EXAI) announces a new discovery stage programme with Sanofi, aiming to design a potential best-in-class molecule. Exscientia is eligible for up to $45 million in upfront and preclinical milestone payments, with additional development, regulatory, and sales-based milestone payments of over $300 million and tiered royalties on product sales.

Exscientia plc (Nasdaq: EXAI) received a $2.3 million grant from Open Philanthropy to research harnessing the host interferon response for treating and preventing pandemic influenza. The grant is part of the wider Pandemic Antiviral Discovery initiative, aiming to develop novel antiviral medicines for future pandemics. Exscientia plans to utilize the grant to explore small molecule therapeutics that can activate the interferon response to control influenza and COVID-19 infections. This aligns with the company's commitment to pandemic preparedness, supported by the Bill & Melinda Gates Foundation in 2021.

Exscientia plc (EXAI) management to participate in fireside chat at Evercore ISI HealthCONx Conference

EXAI: Exscientia plc (Nasdaq: EXAI) reported recent advancements in their pipeline, collaborations, and operations, along with financial results for Q3 2023. Key highlights include progress in their internal pipeline, new collaborations with Merck KGaA and Sanofi, and updates on their technology and precision medicine initiatives. Financially, revenue for Q3 2023 was $10.8 million, with R&D expenses at $39.8 million and G&A expenses at $13.6 million. Net operating cash outflows for the first nine months of 2023 were $145.1 million, with a cash balance of $447.8 million as of September 30, 2023.

Exscientia plc (Nasdaq: EXAI) will report financial results for the third quarter ended September 30, 2023, on November 9, 2023. The company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results. Investors can access the webcast on the company's website or join the conference call using the provided dial-in numbers.